Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis
JAMA Dermatology · 10.11.2026
DOI: 10.1001/jamadermatol.2026.5444 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, online erschienen am 10.11.2026. Verfasst von Misha Rosenbach und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Perelman School of Medicine, Philadelphia, Pennsylvania. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Cutaneous sarcoidosis (CS) is a chronic granulomatous skin disease associated with substantial morbidity and no approved therapies.
Objective
To evaluate the efficacy and safety of brepocitinib, an oral, selective, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with CS. Design, Setting, and Participants BEACON is an ongoing, global, multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial. This prespecified interim analysis evaluated the 16-week, dose-ranging phase 2 portion of the study conducted between April 9, 2025, and July 18, 2025. Adults with biopsy-proven active CS were randomized 3:2:2 to receive brepocitinib, 45 mg; brepocitinib, 15 mg; or placebo once daily. Main Outcomes and Measures The primary efficacy outcome was change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument–Activity (CSAMI-A) score at week 16. Additional outcomes included achievement of Cutaneous Sarcoidosis Activity–Investigator Global Assessment (CSA-IGA) clear or almost clear with a 2 or greater category improvement, CSAMI-A response (≥50% relative improvement), 10-point or greater CSAMI-A score reduction, achievement of a CSAMI-A score less than 5, patient-reported outcomes, and safety.
Results
Thirty-one participants (mean [SD] age, 53.3 [9.6] years; 18 female individuals [58%] and 13 male individuals [42%]) were enrolled. Both brepocitinib doses achieved rapid, significant improvements in CS disease activity: by week 16, CSAMI-A scores improved by 22.3 points in the 45-mg group and 22.2 points in the 15-mg group compared with a 0.7-point improvement with placebo ( P < .001). Across increasingly stringent responder-based and cutaneous remission–oriented end points, efficacy consistently favored brepocitinib, 45 mg, supporting a dose-dependent treatment effect. Compared with placebo, brepocitinib, 45 mg, resulted in higher rates of CSA-IGA clear or almost clear disease (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reduction (100% vs 14.3%; P < .001), and achievement of a CSAMI-A score of less than 5 (61.5% vs 0%; P = .005). Clinical benefit extended to difficult to treat phenotypes, including lupus pernio, despite protocol-mandated systemic glucocorticoid discontinuation, and was accompanied by substantial improvements in skin-related quality of life. No deaths or serious adverse events occurred. Conclusions and Relevance In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 evaluation. Trial Registration ClinicalTrials.gov Identifier: NCT06978725
Autor:innen und Institutionen
- Department of Dermatology, Perelman School of Medicine, Philadelphia, Pennsylvania.
- Department of Dermatology, The School of Medicine and Public Health, University of Wisconsin-Madison, Madison.
- Department of Dermatology, The University of North Carolina-Chapel Hill, Chapel Hill.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina.
- Department of Dermatology, Duke University School of Medicine, Durham, North Carolina.
- Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Zitieren
APA
Rosenbach, M., Shields, B. E., Coates, M., Obi, O. N., Marano, A. L., Mangold, A. R., Onajin, O., Haemel, A., Fivenson, D., Culver, D. A., Judson, M. A., Hannah, C., Smuda, C., Polly, S., Unwala, R., Harper, L., Neto, M. L. R., James, W. E., Vakharia, P., …, & Damsky, W. (2026). Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.5444
Vancouver
Rosenbach M, Shields BE, Coates M, Obi ON, Marano AL, Mangold AR, et al. Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.5444
BibTeX
@article{Rosenbach2026,
author = {Rosenbach, Misha and Shields, Bridget E and Coates, Margaret and Obi, Ogugua Ndili and Marano, Anne L and Mangold, Aaron R and Onajin, Oluwakemi and Haemel, Anna and Fivenson, David and Culver, Daniel A and Judson, Marc A and Hannah, Claire and Smuda, Craig and Polly, Samantha and Unwala, Rashmi and Harper, Logan and Neto, Manuel L Ribeiro and James, W Ennis and Vakharia, Paras and Nguyen, Cuong V and Foulke, Galen and Al-Awqati, Mina and Helm, Matthew and Hsu, Sylvia and Gupta, Rohit and Culton, Donna A and Pariser, Robert and Talia, Jordan and Baker, Matthew C and Shaw, Katharina S and Johnson, Brendan and Cascino, Matthew D and Mandell, Brian and Sweiss, Nadera and Graham, Lauren and Barney, Joseph and Imadojemu, Sotonye and Caplan, Avrom S and Damsky, William},
title = {Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2026.5444}
}
EUVIMED